共查询到20条相似文献,搜索用时 31 毫秒
1.
Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma 总被引:5,自引:0,他引:5
Miller AR Thomason VE Yeh IT Alrahwan A Sharkey FE Stauffer J Otto PM McKay C Kahlenberg MS Phillips WT Cruz AB 《Annals of surgical oncology》2002,9(3):243-247
Background Sentinel lymph node mapping (SLNM) and neoadjuvant chemotherapy are becoming established components of therapy for selected
patients with breast carcinoma. However, neoadjuvant therapy has been considered a relative contraindication to SLNM. In an
effort to learn whether patients who have received preoperative chemotherapy can undergo accurate SLNM, we evaluated our experience
with this technique.
Methods From January 1997 to June 2000, SLNM and axillary lymph node dissection were concurrently performed in 35 patients who received
preoperative chemotherapy. Mapping was performed with99mTc sulfur colloid only in one patient and Lymphazurin dye only in 15 patients, and the two methods were combined in the remainder.
Results SLNM successfully identified a sentinel lymph node in 30 (86%) patients. Metastatic disease was identified in the sentinel
lymph nodes of four patients during surgery. The intraoperative pathologic diagnosis proved to be correct in 19 (79%) of 24
patients. The final pathologic diagnosis of the sentinel lymph node reflected the status of the axillary contents in all patients
in whom it was identified.
Conclusions These results demonstrate that SLNM can be consistently performed in patients receiving preoperative chemotherapy for breast
cancer, suggesting the utility of this technique in this patient populations.
Presented at the 54th Annual Meeting of the Society of Surgical Oncology, Washington, DC, March 15–18, 2001. 相似文献
2.
An argument against routine sentinel node mapping for DCIS 总被引:1,自引:0,他引:1
Farkas EA Stolier AJ Teng SC Bolton JS Fuhrman GM 《The American surgeon》2004,70(1):13-7; discussion 17-8
Indications for sentinel lymph node mapping (SLNM) for patients with ductal carcinoma in situ (DCIS) of the breast are controversial. We reviewed our institutional experience with SLNM for DCIS to determine the node positive rate and clarify indications for nodal staging in patients with DCIS. Since 1998 we have used SLNM to stage breast cancer patients using both blue dye and radiocolloid. In DCIS patients, SLNM has been reserved for patients considered at high risk for harboring coexistent invasive carcinoma or treated by mastectomy. All sentinel nodes were evaluated with serial sectioning, hematoxylin and eosin staining, and immunohistochemical evaluation for cytokeratins. We identified 44 patients with 46 cases of DCIS (two patients with bilateral disease). SLNM identified at least one sentinel node in all cases. In all cases, the sentinel node(s) were negative for axillary metastasis. We calculated the binomial probability of observing 0 of 46 cases as negative when the expected incidence according to published reports in the surgical literature was 13 per cent and found a P value of <0.01. Based on this case-series observation, we conclude SLNM should not be routinely performed for patients with DCIS. We now use SLNM only for DCIS patients treated by mastectomy. 相似文献
3.
Brady EW 《The breast journal》2002,8(2):97-100
The purpose of this study was to evaluate the feasibility of sentinel lymph node mapping in patients undergoing neoadjuvant chemotherapy for breast carcinoma prior to lumpectomy or mastectomy and sentinel lymph node mapping followed by complete axillary dissection. A retrospective analysis of 14 patients from February 1998 to July 2000 with stage I to stage IIIB breast cancer diagnosed by core biopsy underwent neoadjuvant chemotherapy (doxorubicin/cyclophosphamide) prior to definitive surgery, including lumpectomy or mastectomy and sentinel lymph node mapping, followed by full axillary dissection. Thirteen of 14 patients had successful sentinel lymph node identification (93%), and all 14 underwent full axillary dissection. An average of 2.2 sentinel nodes and a median of 16 axillary lymph nodes (including sentinel nodes) were found per patient. Of the 13 patients in whom a sentinel lymph node was identified, 10 were positive for metastases (77%). Only 4 of the 10 had further axillary metastases (40%). Three patients had negative sentinel lymph nodes shown by hematoxylin and eosin and cytokeratin stainings and had no axillary metastases (0% false negative). The single patient in whom a sentinel lymph node could not be identified had stage IIIA disease with extensive lymphatic tumor emboli. Sentinel lymph node mapping is feasible in neoadjuvant chemotherapy breast cancer patients and can spare a significant number of patients the morbidity of full axillary dissection. Further study to evaluate sentinel lymph node mapping in this patient population is warranted. 相似文献
4.
Des Guetz G Uzzan B Nicolas P Cucherat M de Mestier P Morere JF Breau JL Perret G 《World journal of surgery》2007,31(6):1306-1314
The diagnostic value of sentinel lymph node mapping (SLNM) in patients with colorectal cancer (CRC) is controversial. Prognostic
factors for CRC must be detected to improve its treatment. A PubMed query (key words: colorectal cancer, sentinel node) provided
182 studies on the sentinel lymph node (SLN) for CRC, the abstracts of which were reviewed. Altogether, 48 studies dealing
with the diagnostic value of SLNM were selected from PubMed, and 6 other studies were retrieved from reviews. We compared
the diagnostic value of SLNM with that of conventional histopathologic examination. We used the diagnostic accuracy odds ratio
(DAOR) method. Because of significant heterogeneity, we chose the random effect model (Der Simonian and Laird). Statistics
were performed on 33 studies, including 1794 patients (1201 colon and 332 rectum cancers). The mean SLNM failure rate was
10%. The global sensitivity and specificity of the SLNM were, respectively, 70% and 81%. The pooled DAOR was 10.7 (95% confidence
interval 7.0–16.5). That means that a patient whose SLN is invaded has 10.7 times more risk to be node-positive than an SLN-negative
patient. Lymphatic mapping appears to be readily applicable to CRC. One of the main reasons for the heterogeneity is the performance
of the SLNM by Saha et al., whose data had better sensitivity (90%) than those in other studies. The SLNM technique should
be better standardized in future studies. Understanding the cause of false-negative SLNs (9%) is a major issue to resolve
before routinely using this technique in CRC management. The prognostic implication of micrometastases found in SLNs requires
further evaluation. 相似文献
5.
目的 评价乳晕下亚甲兰注射检测乳腺癌哨兵淋巴结。 方法 2 0例早期乳腺癌患者应用亚甲兰乳晕下注射检测哨兵淋巴结。 结果 哨兵淋巴结检出率 95 % (19/ 2 0 )。预测腋窝淋巴结转移准确率为 94 7% (18/ 19)。 结论 乳晕下注射染料检测哨兵淋巴结为最佳途径 ,亚甲兰可以用于哨兵淋巴结检测。 相似文献
6.
Aim Sentinel lymph node mapping has been used in colon cancer to improve prognosis. This study aimed to determine the accuracy of in vivo SLNM in patients with colon carcinoma undergoing surgery with curative intent. Method Thirty‐one patients operated for colon carcinoma underwent in vivo sentinel lymph node mapping using patent blue dye. Each sentinel lymph node (SLN) was marked intraoperatively, and histological examination was performed after en bloc resection. If no metastasis was found, step sectioning with immunohistochemistry was performed. Results The SLN was successfully identified in 28 (90%) of 31 patients. The false‐negative rate to identify stage III disease was 66% (eight of 12), the negative predictive value was 46% (19 of 27) and the accuracy was 14% (four of 28). One patient negative on routine histopathology had micrometastasis on step sectioning of the SLN. Conclusion Sentinel lymph node mapping in colon carcinoma cannot accurately predict nodal status. 相似文献
7.
Lymphatic mapping improves staging and reduces morbidity in women undergoing total mastectomy for breast carcinoma 总被引:2,自引:0,他引:2
Lymphatic mapping (LM) and sentinel lymph node biopsy (SLNB) have become widely accepted in the setting of breast conservation surgery. We hypothesized that LM can be extended to women undergoing total mastectomy, being technically feasible, yielding highly accurate and sensitive results, improving axillary staging, and reducing postoperative morbidity. Between 1995 and 2003, 99 women (mean age 59 years, range 34-87) underwent 100 mastectomies with LM using blue dye alone. Fifty-nine operations (60%) were followed by a completion axillary lymph node dissection (ALND). Ninety per cent of patients had invasive carcinoma; 10 per cent had in situ carcinoma. Mean tumor size was 2.5 cm (range 0.3-8 cm). One hundred fifty-nine sentinel nodes (SNs) (mean 1.65, range 1-5) were successfully identified in 96 (96%) axillae. Twenty-five (25%) sentinel nodes revealed nodal metastases. Five of 25 (20%) SNs had micrometasteses. Three patients had a false-negative SN, yielding a sensitivity of 91 per cent. The accuracy of LM was 97 per cent. No patient who underwent SLNB alone developed lymphedema, axillary seroma formation, infection, or restricted arm movement. This was contrasted with patients undergoing ALND, where 10 (16%) developed lymphedema and 2 (3%) developed an infection. Ten (25%) patients developed axillary paresthesias after SNB compared with 47 (78%) patients after ALND (P < 0.0001). LM in the setting of mastectomy is accurate and sensitive. This technique improves axillary staging and decreases morbidity. Patients who are not candidates for breast conservation should be offered LM and SLNB at the time of mastectomy. 相似文献
8.
Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers 总被引:4,自引:0,他引:4
Ollila DW Neuman HB Sartor C Carey LA Klauber-Demore N 《American journal of surgery》2005,190(3):371-375
BACKGROUND: Lymphatic mapping and sentinel lymphadenectomy (LM/SL) accurately evaluates the axilla in patients with small breast cancers. LM/SL in patients with large breast cancers is controversial. We examined the accuracy of LM/SL prior to neoadjuvant chemotherapy in patients with large (>3.5 cm) breast cancers. METHODS: Patients with large breast cancers underwent LM/SL prior to neoadjuvant chemotherapy using 99m-technetium radiocolloid and isosulfan-blue dye technique. RESULTS: Twenty-one patients with large (median 5.0 cm) breast cancers underwent LM/SL prior to neoadjuvant chemotherapy. Twelve patients had a tumor-free sentinel node (SN) and received doxorubicin-based chemotherapy; 9 patients had disease in the SN and received doxorubicin followed by a taxane. No patient progressed while receiving neoadjuvant chemotherapy, nor has there been an axillary recurrence (median 36 months). CONCLUSIONS: LM/SL performed prior to neoadjuvant chemotherapy in patients with large breast cancers is an accurate method of axillary staging. Axillary staging prior to neoadjuvant chemotherapy may have prognostic and therapeutic implications. 相似文献
9.
Tausch C Steger GG Haid A Jakesz R Fridrik MA Reitsamer R Pöstlberger S Lang A Gnant M Greil R 《The breast journal》2011,17(3):230-238
Over the past years, experience has been increasing with lymphatic mapping and sentinel node biopsy (SNB) after preoperative chemotherapy for breast cancer, with a wide range of results reported in the literature and final conclusions on the diagnostic value and clinical consequences of this sequential approach still missing. Between 1999 and 2002, the Austrian Breast and Colorectal Cancer Study Group (ABCSG) conducted a prospective randomized multicenter trial comparing three versus six preoperative cycles of epirubicin/docetaxel + granulocyte colony-stimulating factor for operable breast cancer. Of the 292 patients recruited to the trial overall, 111 were enrolled in a prospective subprotocol for performing LM and SNB in addition to obligatory axillary lymph node dissection (ALND) after PC. SNB after PC identified at least one sentinel node in 100 of 111 patients (identification rate 90%). In six cases, a false-negative SN was identified, resulting in a false-negative rate of 13% (6 of 47). We only found little correlation between patients and tumor characteristics and the identification rate or false-negative rate. Lymphatic mapping and SNB after primary chemotherapy failed to predict histologic infiltration of the sentinel node with sufficient sensitivity. The routine use of SNB after primary chemotherapy should therefore be discouraged. 相似文献
10.
Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? 总被引:21,自引:0,他引:21
OBJECTIVE: To determine the likelihood of nonsentinel axillary metastasis in the presence of sentinel node metastasis from a primary breast carcinoma. SUMMARY BACKGROUND DATA: Sentinel lymphadenectomy is a highly accurate technique for identifying axillary metastasis from a primary breast carcinoma. Our group has shown that nonsentinel axillary lymph nodes are unlikely to contain tumor cells if the axillary sentinel node is tumor-free, but as yet no study has examined the risk of nonsentinel nodal involvement when the sentinel node contains tumor cells. METHODS: Between 1991 and 1997, axillary lymphadenectomy was performed in 157 women with a tumor-involved sentinel node. Fifty-three axillae (33.5%) had at least one tumor-involved nonsentinel node. The authors analyzed the incidence of nonsentinel node involvement according to clinical and tumor characteristics. RESULTS: Only two variables had a significant impact on the likelihood of nonsentinel node metastasis: the size of the sentinel node metastasis and the size of the primary tumor. The rate of nonsentinel node involvement was 7% when the sentinel node had a micrometastasis (< or =2 mm), compared with 55% when the sentinel node had a macrometastasis (>2 mm). In addition, the rate of nonsentinel node tumor involvement increased with the size of the primary tumor. CONCLUSIONS: If a primary breast tumor is small and if sentinel node involvement is micrometastatic, then tumor cells are unlikely to be found in other axillary lymph nodes. This suggests that axillary lymph node dissection may not be necessary in patients with sentinel node micrometastases from T1/T2 lesions, or in patients with sentinel node metastases from T1a lesions. 相似文献
11.
Previous plastic surgery procedures such as breast augmentation or reduction mammoplasty can potentially alter the lymphatic drainage of the breast. The purpose of this study is to determine the success rates of sentinel node lymphatic mapping in patients with previous plastic surgical procedures of the breast. A total of 83 patients with a history of plastic surgery of the breast that underwent subsequent sentinel node mapping between 1996 and 2008 were retrospectively analyzed. Eight-three patients that underwent a total of 108 sentinel node biopsies. Hundred cases (93%) previously underwent breast augmentation and eight cases (7%) previously underwent reduction mammoplasty. The mean time between the previous plastic surgical procedures and the sentinel node biopsy was 10.3 years (range: 2 months-32 years). Indications for the mapping procedure were invasive cancer (n = 64), ductal carcinoma in situ (n = 17), and prophylactic mastectomy (n = 27). The identification rate of the sentinel node was 95.3% (103/108). The success rate based on type of procedure was 96% (96/100) for augmentation and 87.5% (7/8) for reduction mammoplasty. With a mean follow-up of 3.4 years, there has been only one local axillary recurrence that occurred at the time of an ipsilateral breast recurrence following lumpectomy. Lymphatic mapping can be successfully performed in patients who have previously undergone plastic surgery operations. 相似文献
12.
Xing Y Cormier JN Kuerer HM Hunt KK 《Asian journal of surgery / Asian Surgical Association》2004,27(4):262-267
Breast cancer is a significant health problem worldwide and is one of the leading causes of cancer-related mortality in women. Preoperative chemotherapy has become the standard of care for patients with locally advanced disease and is being used more frequently in patients with early-stage breast cancer. Sentinel lymph node biopsy has shown great promise in the surgical management of breast cancer patients, but its use following preoperative chemotherapy is yet to be determined. Eleven studies have been published with respect to the accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy. Ten studies showed favourable results, with the ability to identify a sentinel lymph node in 84% to 98% of cases, and reported false negative rates ranging from 0% to 20%. The accuracy of sentinel lymph node biopsy following preoperative chemotherapy for breast cancer ranges from 88% to 100%, with higher rates when specific techniques and inclusion criteria are applied. The published literature supports the use of sentinel lymph node biopsy for assessment of the axilla in patients with clinically node-negative disease following preoperative chemotherapy. 相似文献
13.
Newman EA Sabel MS Nees AV Schott A Diehl KM Cimmino VM Chang AE Kleer C Hayes DF Newman LA 《Annals of surgical oncology》2007,14(10):2946-2952
Background The optimal strategy for incorporating lymphatic mapping and sentinel lymph node biopsy into the management of breast cancer
patients receiving neoadjuvant chemotherapy remains controversial. Previous studies of sentinel node biopsy performed following
neoadjuvant chemotherapy have largely reported on patients whose prechemotherapy, pathologic axillary nodal status was unknown.
We report findings using a novel comprehensive approach to axillary management of node-positive-patients receiving neoadjuvant
chemotherapy.
Methods We evaluated 54 consecutive breast cancer patients with biopsy-proven axillary nodal metastases at the time of diagnosis that
underwent lymphatic mapping with nodal biopsy as well as concomitant axillary lymph node dissection after receiving neoadjuvant
chemotherapy. All cases were treated at a single comprehensive cancer center between 2001 and 2005.
Results The sentinel node identification rate after delivery of neoadjuvant chemotherapy was 98%. Thirty-six patients (66%) had residual
axillary metastases (including eight patients that had undergone resection of metastatic sentinel nodes at the time of diagnosis),
and in 12 cases (31%) the residual metastatic disease was limited to the sentinel lymph node. The final, post-neoadjuvant
chemotherapy sentinel node was falsely negative in three cases (8.6%). The negative final sentinel node accurately identified
patients with no residual axillary disease in 17 cases (32%).
Conclusions Sentinel lymph node biopsy performed after the delivery of neoadjuvant chemotherapy in patients with documented nodal disease
at presentation accurately identified cases that may have been downstaged to node-negative status and can spare this subset
of patients (32%) from experiencing the morbidity of an axillary dissection. 相似文献
14.
A patient with an accessory breast on the anterior abdominal wall was found to have cancer of this tissue, because of its unusual position it was decided that lymphatic mapping was necessary to identify the lymphatic drainage of this tumour. A metastasis was found in a sentinel node deep to the 'true' ipsilateral breast; however, the sentinel node identified in the axilla of this patient was free of metastases. The use of the sentinel node technique up staged the cancer from I to II and the patient went on to have adjuvant treatment with chemotherapy. The use of lymphatic mapping and sentinel node biopsy in the case of cancer of an accessory breast allows more accurate determination of lymph node status. 相似文献
15.
Lymphatic mapping and sentinel lymphadenectomy for breast cancer 总被引:9,自引:0,他引:9
Lymphatic mapping and sentinel lymphadenectomy has become an important tool for axillary lymph node staging in women with early-stage breast cancer. This review examines data regarding the staging accuracy, indications and technical aspects of the procedure, and clinical trials investigating the technique. Multiple studies now confirm that sentinel lymphadenectomy accurately stages the axilla and is associated with less morbidity than axillary dissection. Blue dye, radiocolloid, or both can be used to identify the sentinel node, and several injection techniques may be used successfully. Many patient factors previously thought to affect accuracy of the procedure have now been shown to be of limited significance. The indications for the procedure are expanding, and the histopathologic evaluation of the sentinel node and the role of lymphoscintigraphy have been clarified. Clinical trials are now underway that will determine the prognostic significance of micrometastases and the therapeutic benefit of axillary dissection in women with and without sentinel node metastases. Incorporation of sentinel lymphadenectomy into routine clinical practice will maintain accurate axillary staging with lower morbidity and improved quality of life for women with early-stage breast cancer. 相似文献
16.
Is a completion axillary dissection indicated for micrometastases in the sentinel lymph node? 总被引:8,自引:0,他引:8
OBJECTIVE: The purpose of this study is to determine if a completion axillary dissection (CAD) is necessary when microscopic metastasis (<2 mm) is detected in the sentinel lymph node (SLN) of patients diagnosed with breast cancer. METHODS: A retrospective chart review was performed on 227 consecutive breast cancer patients who underwent SLN mapping (SLNM) between June 1998 and March 2001. These patients underwent intraoperative lymphatic mapping with peritumoral injections of blue dye alone or in combination with technetium-labeled sulfur colloid. The SLN was assessed by touch preparation or frozen section at the time of surgery, and later, by hematoxylin and eosin stain. Patients in whom the SLN showed evidence of metastatic disease on frozen section underwent immediate CAD. RESULTS: One patient was excluded because of inability to identify the SLN. Of the 226 patients in whom SLNM was successful, 67 (27%) had macrometastasis in the SLN, and a completion CAD was performed. Thirty-four of these 67 patients (51%) had additional disease in the axilla. A total of 15 patients (6.7%) was determined to have micrometastasis. In 11 patients, micrometastasis was identified and CAD was performed with no further evidence of disease. The 4 patients diagnosed with micrometastatic disease on permanent staining did not have further surgical intervention. The 15 patients identified with micrometastasis show no evidence of local recurrence to date, with a mean follow-up of 13.5 months (range 1 to 27). CONCLUSIONS: This study suggests that CAD may not be necessary for the subset of breast cancer patients with micrometastasis detected upon SLNM. A larger randomized prospective study with long-term follow up is necessary to confirm these data. 相似文献
17.
�� �ϣ���־�� 《中国实用外科杂志》2018,38(11):1254-1260
??Problems and treatment options of sentinel lymph node in breast cancer WU Di, FAN Zhi-min. Department of Breast Surgery??the First Hospital of Jilin University??Changchun 130021??China
Corresponding author: FAN Zhi-min, E-mail:fanzhimn@163.com
Abstract Sentinel lymph node biopsy (SLNB) has been the primary care in clinically node negative breast cancer. Controversy still surrounds the SLNB of the internal mammary nodes. Because different kinds of tracer have respective feature, surgeons should choose the suitable tracer. All blue lymph nodes and any lymph nodes at the end of a blue lymphatic channel should be removed and designated as SLNs.Clinicians should not recommend ALND for women with early-stage breast cancer who have one or two SLN metastases and will receive breast-conserving surgery with conventionally fractionated whole-breast radiotherapy.Clinicians may offer ALND for women with early-stage breast cancer with nodal metastases found on SNB who will receive mastectomy. For patients who recieved neoadjuvant chemotherapy, SLNB after neoadjuvant chemotherapy is optimal. 相似文献
18.
Lymphatic mapping and sentinel node biopsy: is the method applicable to patients with colorectal and gastric cancer? 总被引:3,自引:0,他引:3
M Th?rn 《Acta chirurgica》2000,166(10):755-758
The current status of lymphatic mapping and sentinel node biopsy in the treatment of patients with malignant melanoma and breast cancer is described. The possible use of a similar method in patients with colorectal and gastric cancer is outlined. Peroperative lymphatic mapping and identification of sentinel node(s) in patients with gastrointestinal cancer may lead to modified (tailored) resections and extended lymph node dissections only in those patients in whom the sentinel node(s) contains tumour cells. The method offers the possibility of improving staging by identification of patients with early disseminated disease who should be considered for adjuvant treatment or be included in trials of adjuvant treatment to speed up the breakthrough of more effective adjuvant regimens. Large studies are needed to find out if the sentinel node concept is as valid in gastrointestinal cancer as studies so far have shown that it is for malignant melanoma and breast cancer. 相似文献
19.
R J Gray R Giuliano E L Dauway C E Cox D S Reintgen 《American journal of surgery》2001,182(4):404-406
BACKGROUND: Radioguided surgery can also be used for the simultaneous guidance to a nonpalpable primary tumor and sentinel lymph nodes. METHODS: Retrospective review of a prospective database. The surgeon used a gamma probe for guidance to an iodine-125 labeled titanium seed at the primary lesion and technetium-99 labeled sulfur colloid at the sentinel lymph node. RESULTS: Forty-three patients with nonpalpable breast carcinoma underwent dual isotope radioguided surgery. The radioactive seed and primary lesion were retrieved in the first excision in all 44 patients (100%). Eleven patients (25%) had pathologically involved margins. Sentinel lymph node mapping was successful in 42 patients (98%). A mean of 2.4 sentinel nodes were excised and metastatic carcinoma was present in four patients (10%). CONCLUSIONS: Dual isotopes can be effectively used in breast cancer patients for simultaneous radioguidance to both a nonpalpable primary lesion and sentinel lymph node and allows for improved logistics. 相似文献
20.
D Dequanter D Hertens I Veys J M Nogaret D Larsimont P Bourgeois 《Annales de chirurgie》2001,126(7):654-658
STUDY AIM: Determination of axillary lymph node status is crucial in diagnosis of early breast cancer. However thanks to an early diagnosis, an increasing number of axillary lymph node dissections are free of disease. This raises questions about the need for this procedure. The study aim was to report an experience with lymphadenectomy and sentinel node mapping in patients with T0-T1 carcinoma of the breast. METHODS: Between November 1997 and December 1999, 84 consecutive women (T0-T1 N0 according to the 1987 UICC classification) with recently diagnosed breast cancer, were included in this study for identification of the sentinel lymph node (SLN). The SLN was removed and submitted for histological examination. All patients underwent axillary dissection; nodes from levels I and II (Berg's classification) were excised and submitted to histological examination. RESULTS: The average tumor diameter was 12.7 mm (range, 3 to 25 mm). The lymphatic mapping technique was obtained after injection of the isotope into the breast around the tumor in 53/84 patients: the sentinel lymph node was the only positive node in 10 patients and it was positive in 5 patients with other axillary nodes. In 15/84 patients, an intradermal injection of blue dye was used; two sentinel nodes were positive and one falsely negative. In 16/84 patients, an interdermal injection of blue dye was used to make up for. In this study, the sentinel node was positive in three patients and falsely negative in one patient. The discrepancy was due to an important involvement of an axillary area excluded from the lymphatic channels. 22/84 patients (26%) had a metastatic spread to the axillary nodes. 30/84 patients had also an isotopic captation in another lymph node group (internal mammary). CONCLUSION: This study confirms that lymphatic mapping is technically possible in the patients with T0-T1 breast cancer and that the histological characteristics of the sentinel node probably reflect the histological characteristics of the rest of the axillary lymph nodes, but do not provide any information about the other lymph node sites. 相似文献